Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 0.89 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amibegron SCHEMBL9316758 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897918 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2335210 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29380172 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2335205 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9317343 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3898164 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL8765764 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1382333-B1 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | ASTELLAS PHARMA INC (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | ADRB3 12/4885ADRB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.